Related Experiment Video
Updated: Mar 16, 2026
Correlating Gene-specific DNA Methylation Changes with Expression and Transcriptional Activity of Astrocytic KCNJ10 Kir4.1
Published on: September 26, 2015
A tissue microarray study of toll-like receptor 4, decoy receptor 3, and external signal regulated kinase 1/2
Chih-Kung Lin1, Chun-Chieh Ting2, Wen-Chiuan Tsai3
1Department of Pathology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan, Republic of China.
Introduction:
Decoy receptor 3 (DcR3) functions as a death decoy inhibiting apoptosis mediated by the tumor necrosis factor receptor family. It is highly expressed in many tumors and its expression can be regulated by the MAPK/ERK signaling pathway and ERK is a vital member of this pathway. Toll-like receptor 4 (TLR4) is expressed on immune cells. Increased TLR4 expression has been associated with various types of cancers.
Material And Methods:
The study was conducted to investigate the expression of DcR3, ERK1/2, and TLR4 in astrocytomas and evaluate if they are validating markers for discriminating glioblastoma from anaplastic astrocytoma in limited surgical specimen. Expression of DcR3, ERK1/2, and TLR4 was determined by immunohistochemical staining of tissue microarray from 48 paraffin-embedded tissues. A binary logistic regression method was used to generate functions that discriminate between anaplastic astrocytomas and glioblastomas.
Results:
The expression of TLR4 and DcR3 was significantly higher in glioblastomas than in anaplastic astrocytomas. DcR3 could discriminate anaplastic astrocytomas from glioblastomas with high sensitivity (93.8%), specificity (90%), and accuracy (92.3%).
Conclusion:
Our results suggest that DcR3 may be a useful marker for discriminating anaplastic astrocytomas from glioblastomas.
Insights
Decoy receptor 3 (DcR3) and Toll-like receptor 4 (TLR4) show higher expression in glioblastomas. DcR3 is a potential biomarker for distinguishing glioblastomas from anaplastic astrocytomas.
Area of Science:
- Neuro-oncology
- Cancer biology
- Immunology
Background:
- Decoy receptor 3 (DcR3) inhibits apoptosis and is upregulated in many tumors.
- Toll-like receptor 4 (TLR4) is implicated in various cancers.
- The MAPK/ERK pathway influences DcR3 expression.
Purpose of the Study:
- To investigate the expression of DcR3, ERK1/2, and TLR4 in astrocytomas.
- To evaluate their utility as biomarkers for differentiating glioblastoma from anaplastic astrocytoma.
Main Methods:
- Immunohistochemical staining of tissue microarrays from 48 astrocytoma samples.
- Analysis of DcR3, ERK1/2, and TLR4 expression.
- Binary logistic regression for discrimination analysis.
Main Results:
- Significantly higher expression of TLR4 and DcR3 in glioblastomas compared to anaplastic astrocytomas.
- DcR3 demonstrated high sensitivity (93.8%), specificity (90%), and accuracy (92.3%) in discriminating between the two tumor types.
Conclusions:
- DcR3 shows promise as a valuable biomarker for differentiating anaplastic astrocytomas from glioblastomas.
- Further validation may establish DcR3 as a diagnostic tool in neuro-oncology.
More Related Videos
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
